文献速递糖尿病肥胖与代谢综合征

每周一次司美格鲁肽对比每日一次卡格列净对2型糖尿病患者身体成分的影响:SUSTAIN 8随机对照临床试验的子研究

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
PubMed 文献 · Diabetologia · 2020-01-02

SUSTAIN 8子研究纳入178例接受稳定剂量二甲双胍的2型糖尿病患者,随机接受司美格鲁肽1.0 mg每周一次或卡格列净300 mg每日一次,52周时全身双能X线吸收法评估身体成分。两组总脂肪量分别减少3.4 kg和2.6 kg,估计治疗差异为-0.79 kg(95%CI -2.10, 0.51),身体成分变化无显著差异。

要点

  • 司美格鲁肽组总脂肪量减少3.4 kg,卡格列净组减少2.6 kg,组间差异无统计学意义。
  • 两组瘦体重比例分别增加1.2和1.1个百分点,内脏脂肪量变化两组相当。
  • 作者指出,因缺乏安慰剂对照,两种药物对身体成分的具体影响尚属推测。

核心结论

  • 在接受稳定剂量二甲双胍治疗且血糖控制不佳的2型糖尿病患者中,司美格鲁肽与卡格列净对身体成分的改变无显著差异。
  • 尽管两治疗组均观察到身体成分的数值改善,但在缺乏安慰剂对照的情况下,两种治疗对身体成分的具体影响目前尚属推测。

研究设计与样本

  • SUSTAIN 8 IIIB期随机双盲试验的子研究,受试者为年龄≥18岁、HbA1c 53-91 mmol/mol(7.0-10.5%)、接受稳定每日剂量二甲双胍(≥1500 mg或最大耐受剂量)且eGFR≥60 ml min-1 [1.73 m]-2的2型糖尿病成人。
  • 受试者按1:1随机分配至司美格鲁肽1.0 mg每周一次加卡格列净安慰剂每日一次,或卡格列净300 mg每日一次加司美格鲁肽安慰剂每周一次。
  • 178例参与者(司美格鲁肽组n=88,卡格列净组n=90)在筛选期接受全身双能X线吸收法(DXA)扫描并随机进入子研究;其中114例(司美格鲁肽组n=53,卡格列净组n=61)有可观察的治疗结束数据纳入确证性疗效分析。
  • 研究参与者和研究者全程设盲,DXA扫描质量以盲法评估。
  • 确证性疗效终点为从基线至第52周总脂肪量(kg)的变化。

主要发现

  • 司美格鲁肽组总脂肪量(基线33.2 kg)减少3.4 kg,卡格列净组减少2.6 kg,估计治疗差异为-0.79(95%CI -2.10, 0.51)。
  • 司美格鲁肽组总瘦体重(基线51.3 kg)减少2.3 kg,卡格列净组减少1.5 kg,估计治疗差异为-0.78(95%CI -1.61, 0.04)。
  • 司美格鲁肽组瘦体重比例(基线59.4%)增加1.2个百分点,卡格列净组增加1.1个百分点,估计治疗差异为0.14(95%CI -0.89, 1.17)。
  • 内脏脂肪量变化及以脂肪与瘦体重比值评估的身体成分总体变化在两组间相当。

局限性

  • 原文指出,在缺乏安慰剂对照的情况下,两种治疗对身体成分的具体影响目前尚属推测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a subset of participants from the SUSTAIN 8 Phase IIIB, randomised double-blind trial who underwent whole-body dual-energy x-ray absorptiometry (DXA) scanning. METHODS: Adults (age ≥18 years) with type 2 diabetes, HbA1c 53-91 mmol/mol (7.0-10.5%), on a stable daily dose of metformin (≥1500 mg or maximum tolerated dose) and with an eGFR ≥60 ml min-1 [1.73 m]-2 were randomised 1:1 to semaglutide 1.0 mg once weekly and canagliflozin placebo once daily, or canagliflozin 300 mg once daily and semaglutide placebo once weekly. Body composition was assessed using whole-body DXA scans. The study participants and investigator remained blinded throughout the trial, and quality of DXA scans was evaluated in a blinded manner. Change from baseline to week 52 in total fat mass (kg) was the confirmatory efficacy endpoint. RESULTS: A subset of 178 participants (semaglutide, n = 88; canagliflozin, n = 90) underwent DXA scanning at screening and were randomised into the substudy. Of these, 114 (semaglutide, n = 53; canagliflozin, n = 61) participants had observed end-of-treatment data included in the confirmatory efficacy analysis. Of the 178 participants in the substudy, numerical improvements in body composition (including fat mass, lean mass and visceral fat mass) were observed after 52 weeks with both treatments. Total fat mass (baseline 33.2 kg) was reduced by 3.4 kg and 2.6 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: -0.79 [95% CI -2.10, 0.51]). Although total lean mass (baseline 51.3 kg) was also reduced by 2.3 kg and 1.5 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: -0.78 [-1.61, 0.04]), the proportion of lean mass (baseline 59.4%) increased by 1.2%- and 1.1%-point, respectively (estimated treatment difference 0.14 [-0.89, 1.17]). Changes in visceral fat mass and overall changes in body composition (assessed by the fat to lean mass ratio) were comparable between the two treatment groups. CONCLUSIONS/INTERPRETATION: In individuals with uncontrolled type 2 diabetes on stable-dose metformin therapy, the changes in body composition with semaglutide and canagliflozin were not significantly different. Although numerical improvements in body composition were observed following treatment in both treatment arms, the specific impact of both treatments on body composition in the absence of a placebo arm is speculative at this stage. TRIAL REGISTRATION: ClinicalTrials.gov NCT03136484. FUNDING: This trial was supported by Novo Nordisk A/S, Denmark.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. McCrimmon RJ, Catarig AM, Frias JP, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020. PMID: 31897524. doi:10.1007/s00125-019-05065-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。